Bioequivalence of Anti-Epileptic Drugs Established

Study Overview

Recent research has confirmed that three anti-epileptic drugs, including one branded version of Lamotrigine and two generic counterparts, are bioequivalent. This finding assures healthcare professionals that branded and generic medications can be substituted with confidence.

Prevalence of Generic Prescriptions

It is noteworthy that approximately 80% of prescriptions filled in the United States are for generic drugs. The U.S. Food and Drug Administration (FDA) mandates that generic medications must contain the same active ingredients, strength, dosage form, and route of administration as their branded counterparts, a principle known as bioequivalence.

Responsibilities of Generic Manufacturers

Generic drug manufacturers are tasked with demonstrating that their products are bioequivalent to branded drugs. This is typically accomplished through studies in which patients take the generic medication, and the drug concentration in the bloodstream is measured. If the blood levels of the generic match those of the branded version, it is expected that the generic will perform similarly.

Research Methodology

To investigate the bioequivalence of the anti-epileptic drug lamotrigine, a research team led by Michael Berg from the University of Rochester conducted a randomized clinical trial involving 50 adults with epilepsy. This study, named the Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy (EQUIGEN) randomized control trial, has been published in JAMA Neurology.

Pharmacokinetic Measures

The evaluation of equivalence between generic and branded drug products is based on two crucial pharmacokinetic (PK) measures: the area under the concentration curve (AUC) and the maximal concentration (Cmax). For drugs to be considered bioequivalent, the 90% confidence interval of the ratios of the generic to the branded drug for both AUC and Cmax must fall within the range of 80% to 125%.

Study Findings

In this study, the single-dose PK profiles of two generic lamotrigine products and one branded lamotrigine drug were compared in patients, including adults with refractory epilepsy. Data from 49 patients were analyzed, revealing no significant differences in the PK profiles among the branded lamotrigine and its two generic counterparts.

Statistical Analysis and Conclusions

The comparison of high and low doses of the generic drug against the branded product, as well as between different doses of the generic product, demonstrated that the 90% confidence intervals for relative bioavailability remained within the 80% to 125% equivalence limits for both AUC and Cmax. Notably, potential confounders such as treatment sequence, study period, and age did not affect the bioequivalence results.

Implications for Healthcare Professionals

The significance of this study lies in its potential to empower doctors and pharmacists to confidently prescribe the generic version of lamotrigine. The findings confirm that, despite the participants exhibiting multiple clinically relevant variables, the PK profiles adhered to the bioequivalence standards established by the FDA.

Author Information

Written by Joseph M. Antony, PhD.